258 related articles for article (PubMed ID: 18693018)
1. Design and SAR of new substituted purines bearing aryl groups at N9 position as HIV-1 Tat-TAR interaction inhibitors.
Pang R; Zhang C; Yuan D; Yang M
Bioorg Med Chem; 2008 Sep; 16(17):8178-86. PubMed ID: 18693018
[TBL] [Abstract][Full Text] [Related]
2. The design, synthesis, and biological evaluation of novel substituted purines as HIV-1 Tat-TAR inhibitors.
Yuan D; He M; Pang R; Lin SS; Li Z; Yang M
Bioorg Med Chem; 2007 Jan; 15(1):265-72. PubMed ID: 17055732
[TBL] [Abstract][Full Text] [Related]
3. Design, synthesis, and biological evaluation of novel quinoline derivatives as HIV-1 Tat-TAR interaction inhibitors.
Chen S; Chen R; He M; Pang R; Tan Z; Yang M
Bioorg Med Chem; 2009 Mar; 17(5):1948-56. PubMed ID: 19217787
[TBL] [Abstract][Full Text] [Related]
4. Alpha,alpha-trehalose derivatives bearing guanidino groups as inhibitors to HIV-1 Tat-TAR RNA interaction in human cells.
Wang M; Xu Z; Tu P; Yu X; Xiao S; Yang M
Bioorg Med Chem Lett; 2004 May; 14(10):2585-8. PubMed ID: 15109657
[TBL] [Abstract][Full Text] [Related]
5. Synthesis and assay of isoquinoline derivatives as HIV-1 Tat-TAR interaction inhibitors.
He M; Yuan D; Lin W; Pang R; Yu X; Yang M
Bioorg Med Chem Lett; 2005 Sep; 15(17):3978-81. PubMed ID: 16039124
[TBL] [Abstract][Full Text] [Related]
6. Design, synthesis and bioactivities of TAR RNA targeting beta-carboline derivatives based on Tat-TAR interaction.
Yu X; Lin W; Pang R; Yang M
Eur J Med Chem; 2005 Sep; 40(9):831-9. PubMed ID: 15925430
[TBL] [Abstract][Full Text] [Related]
7. Synthesis and biological evaluation of novel beta-carboline derivatives as Tat-TAR interaction inhibitors.
Yu X; Lin W; Li J; Yang M
Bioorg Med Chem Lett; 2004 Jun; 14(12):3127-30. PubMed ID: 15149658
[TBL] [Abstract][Full Text] [Related]
8. A new class of HIV-1 Tat antagonist acting through Tat-TAR inhibition.
Hamy F; Brondani V; Flörsheimer A; Stark W; Blommers MJ; Klimkait T
Biochemistry; 1998 Apr; 37(15):5086-95. PubMed ID: 9548739
[TBL] [Abstract][Full Text] [Related]
9. New inhibitors of the Tat-TAR RNA interaction found with a "fuzzy" pharmacophore model.
Renner S; Ludwig V; Boden O; Scheffer U; Göbel M; Schneider G
Chembiochem; 2005 Jun; 6(6):1119-25. PubMed ID: 15883975
[TBL] [Abstract][Full Text] [Related]
10. 2-Phenylquinolones as inhibitors of the HIV-1 Tat-TAR interaction.
Gatto B; Tabarrini O; Massari S; Giaretta G; Sabatini S; Del Vecchio C; Parolin C; Fravolini A; Palumbo M; Cecchetti V
ChemMedChem; 2009 Jun; 4(6):935-8. PubMed ID: 19283692
[TBL] [Abstract][Full Text] [Related]
11. Oligonucleotide analogue interference with the HIV-1 Tat protein-TAR RNA interaction.
Arzumanov A; Walsh AP; Liu X; Rajwanshi VK; Wengel J; Gait MJ
Nucleosides Nucleotides Nucleic Acids; 2001; 20(4-7):471-80. PubMed ID: 11563062
[TBL] [Abstract][Full Text] [Related]
12. Amino disaccharides having an alpha-(1-->4) or a beta-(1-->4) linkage, their synthesis and evaluation as a potential inhibitor for HIV-1 TAR-Tat.
Iguchi T; Ishikawa H; Matumoto H; Mizuno M; Goto K; Hamasaki K
Nucleic Acids Symp Ser (Oxf); 2005; (49):169-70. PubMed ID: 17150687
[TBL] [Abstract][Full Text] [Related]
13. Design and synthesis of a novel peptidomimetic inhibitor of HIV-1 Tat-TAR interactions: squaryldiamide as a new potential bioisostere of unsubstituted guanidine.
Lee CW; Cao H; Ichiyama K; Rana TM
Bioorg Med Chem Lett; 2005 Oct; 15(19):4243-6. PubMed ID: 16054360
[TBL] [Abstract][Full Text] [Related]
14. Novel piperidinylpyrimidine derivatives as inhibitors of HIV-1 LTR activation.
Fujiwara N; Nakajima T; Ueda Y; Fujita H; Kawakami H
Bioorg Med Chem; 2008 Nov; 16(22):9804-16. PubMed ID: 18926711
[TBL] [Abstract][Full Text] [Related]
15. Structure-based drug design targeting an inactive RNA conformation: exploiting the flexibility of HIV-1 TAR RNA.
Murchie AI; Davis B; Isel C; Afshar M; Drysdale MJ; Bower J; Potter AJ; Starkey ID; Swarbrick TM; Mirza S; Prescott CD; Vaglio P; Aboul-ela F; Karn J
J Mol Biol; 2004 Feb; 336(3):625-38. PubMed ID: 15095977
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of tat-mediated HIV-1-LTR transactivation and virus replication by sulfhydryl compounds with chelating properties.
Demirhan I; Chandra A; Sarin PS; Hasselmayer O; Hofmann D; Chandra P
Anticancer Res; 2000; 20(4):2513-7. PubMed ID: 10953320
[TBL] [Abstract][Full Text] [Related]
17. A possible improvement for structure-based drug design illustrated by the discovery of a Tat HIV-1 inhibitor.
Montembault M; Vo-Thanh G; Deyine A; Fargeas V; Villiéras M; Adjou A; Dubreuil D; Esquieu D; Grégoire C; Opi S; Péloponèse JM; Campbell G; Watkins J; de Mareuil J; Aubertin AM; Bailly C; Loret E; Lebreton J
Bioorg Med Chem Lett; 2004 Mar; 14(6):1543-6. PubMed ID: 15006399
[TBL] [Abstract][Full Text] [Related]
18. Anti-Tat and anti-HIV activities of trimers of n-alkylglycines.
Márquez N; Sancho R; Macho A; Moure A; Masip I; Messeguer A; Muñoz E
Biochem Pharmacol; 2006 Feb; 71(5):596-604. PubMed ID: 16405868
[TBL] [Abstract][Full Text] [Related]
19. Aromatic polyamidines inhibiting the Tat-induced HIV-1 transcription recognize structured TAR-RNA.
Mischiati C; Jeang KT; Feriotto G; Breda L; Borgatti M; Bianchi N; Gambari R
Antisense Nucleic Acid Drug Dev; 2001 Aug; 11(4):209-17. PubMed ID: 11572598
[TBL] [Abstract][Full Text] [Related]
20. Influence of generation 2-5 of PAMAM dendrimer on the inhibition of Tat peptide/ TAR RNA binding in HIV-1 transcription.
Wang W; Guo Z; Chen Y; Liu T; Jiang L
Chem Biol Drug Des; 2006 Dec; 68(6):314-8. PubMed ID: 17177893
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
